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Abstract
There is a lack of predictive biomarkers that can identify patients with head and neck squa-
mous cell carcinoma (HNSCC) who will experience treatment failure and develop drug resis-
tance, recurrence, and metastases. Cancer stem-like cells (CSC) were identified as a
subset of cells within the tumor in a variety of solid tumors including HNSCC. CSC are con-
sidered the tumor-initiating population responsible for recurrence or metastasis and are
associated with therapy resistance. This meta-analysis including fourteen studies with alto-
gether 1258 patients updates and summarizes all relevant data on the impact of ALDH1+
CSC on the prognosis of HNSCC and its association with clinicopathological parameters.
ALDH1 expression is highly correlated with tumor differentiation (G3 vs. G1+G2; odds
ratio = 2.85. 95% CI: 1.72–4.73, P<0.0001) and decreased overall survival (relative risk =
1.77. 95% CI: 1.41–2.22, P<0.0001) if one out of seven studies was excluded because of
heterogeneity. These findings provide insights into the understanding of more aggressive
tumor phenotypes and also suggest that the prognostic value provided by HNSCC-subtyp-
ing by CSC frequency warrant further clinical investigation.
Introduction
Recent discoveries in cancer research continue to support the theory that cancer stem cells
(CSC) initiate metastasis formation and tumor recurrence after initial therapy [1, 2]. Such a
cancer initiating cell population has not only been described for head and neck squamous
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cell carcinoma (HNSCC) but also proved being relevant for clinical outcome of patients
with such a disease as observed by our group and others [3–5]. HNSCC is regarded one of
the most prevalent malignant diseases worldwide. Multimodal treatment strategies have sub-
stantially improved survival in patients with curative potential [6–9]. However, treatment
decision in clinical routine especially for locally advanced (LA) HNSCC remains a challenge
and is based on conventional factors such as tumor stage, comorbidities and a patient’s
responses to ongoing treatments [10]. Among patients who had LA diseases and even with
similar histopathological characteristics, diversity in responses to the same treatment regi-
men resulting also in differences in prognosis suggests so far unknown determining parame-
ters [11]. Thus, additional stratification factors could augment the TNM staging system to
improve prediction of long-term survival. That is, biomarker stratified treatment strategies
could become a reality. Although HNSCC prognosis, and specifically in oropharyngeal can-
cer (OPSCC), has clearly been influenced by detection of human papilloma virus (HPV)
infection [12], additional biomarkers are needed for HPV-negative tumors. Furthermore, in
case CSC have a predictive or prognostic role for patients with HNSCC as suggested by pre-
clinical studies, the targeting of the CSC cell population in combination with conventional
therapies aiming at a reduction or eradication of the bulk tumor would be a reasonable
approach to improve therapeutic efficacy by prevention of local recurrence or metastasis
formation.
CSC can be defined by their biological features like unlimited proliferative capacity, and
enhanced resistance to conventional treatment modalities like chemotherapy or radiation, by
phenotypical markers like receptor expression, or by indirect detection of specific transmem-
brane transporter molecules. Among these CSC markers, the aldehyde dehydrogenase 1
(ALDH1) isoenzymes, which can be detected by their enzymatic function as well as by immu-
nohistochemistry, are well studied in HNSCC. ALDH1 is associated with a stem cell-like phe-
notype, which is among other mechanisms a direct consequence of its obvious activity for
oxidation of retinal to retinoic acid leading to cell differentiation [13]. Furthermore, ALDH1
expression enhances resistance to several anticancer drugs by its catalytic activity [14]. In cell
lines, ALDH1-positivity is associated with tumorigenesis and resistance to chemo-radiation [4,
15]. ALDH1A1 positive CSCs are found both in primary tumors originating from the oral cav-
ity, oropharynx, hypopharynx and larynx [5] and in lymph node metastases [16, 17]. Clinical
studies have shown the prognostic value of ALDH1A1 in patients with LA HNSCC as well as
in patients with nodal and visceral metastatic disease [5, 17].
Because of the persistence of CSC during therapy, which contributes to tumor relapse and
its capacity for recapitulation of the heterogeneous features of a cancer, eradication of CSC is
viewed as an important challenge for a successful cancer therapy. In a recent ex vivo study,
NCT-501, a theophylline-based inhibitor of ALDH1A1, was able to overcome secondary resis-
tance to several chemotherapeutic agents. The combination with cisplatin treatment was
found to significantly decrease the proliferation of primary HNSCC cells compared to treat-
ment with the individual agents [18]. Moreover, ALDH1A1 has been proven to be immuno-
genic and a target for cytotoxic T-cells. It has been shown that T-cell lines specific for MHC
class I-restricted epitopes of ALDH1A1 can eliminate ALDH1A1 positive cancer cells in
HNSCC [19, 20]. These observations imply a clinical usefulness of ALDH1A1 not only as a
predictive biomarker but as potential target in HNSCC.
In order to assess clinical and biological characteristics such as histological appearance,
lymph node metastasis and patient’s survival in relation to ALDH1 expression in HNSCC, we
conducted a systematic review of the literature and meta-analysis. Strategies targeting ALDH1
positive CSC are also discussed.
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Materials and methods
Literature search strategy and selection criteria
Electronic literature databases PubMed, EMBASE, the Cochrane Library, and WangFang data-
bases for studies published before December 31st, 2016 were searched using the following key
words: “ALDH1” or “aldehyde dehydrogenase 1” and “head and neck squamous cell” or “oral”
or “laryngeal” or “pharyngeal” or “tongue” or “oropharyngeal” and “cancer” or “carcinoma”
or “neoplasms”. Titles and abstracts were scanned to identify the candidate publications. Sys-
tematic reviews, letters, and case studies were excluded. Manuscripts from the reference lists of
original or review articles were also screened for additional publications. In a second step, full-
text articles were assessed to check for eligibility. To be included in the current study, original
articles were required to meet the following criteria: (1) patients with HNSCC; (2) correlations
between ALDH1 overexpression and histopathological parameters, overall survival (OS) or
disease-free survival (DFS) of HNSCC patients were analyzed.
Data extraction
Pivotal data were extracted from all eligible publications independently by two of the authors
(DY and QX). For this, data tables were composed to extract all relevant data from texts, tables
and figures including patient characteristics, tumor stages and additional clinical features
together with clinical endpoints like OS and DFS. Additionally, for each article, the authors,
the year of publication, and the number of patients were extracted. To digitalize and extract
survival data from Kaplan–Meier plot curves, the software GraphClick (Version 3.0.2, Arizona
Software 2010, http://www.arizona-software.ch/graphclick) was used.
Study quality
The Newcastle-Ottawa Scale (NOS), a risk of bias assessment tool for observational studies,
was used to evaluate the methodological quality of included studies [21, 22]. The quality
assessment values ranged from 0 to 9 points. There are three categories including selection
(4 points), comparability (2 points), and exposure (3 points) (S2 Table). The result was an
overall risk of bias rating of each study and score5 is considered high quality [22]. Two inde-
pendent reviewers evaluated the risk of bias for each study.
Statistical analysis
All statistical analyses were performed using the methods described in the Cochrane Hand-
book for Systematic Review of Interventions [23], using the Reviewer Manager Software, ver-
sion 5.3 (Cochrane Library, Oxford, UK) and STATA 12.1 (StataCorp LP, Texas, USA). The
impact of ALDH1 overexpression on dichotomous data was expressed as the odds ratio (OR)
and risk ratio (RR) with 95% Confidence Intervals (CI). OR was used to assess the association
between ALDH1 overexpression and clinicopathological parameters such as clinical stage
including lymph node status and tumor histology. RR was used to assess the association
between ALDH1 overexpression and outcome (OS and DFS) [24].
We assessed the statistical heterogeneity by observing I-squared (I2) and Q test [25, 26]. If a
significant heterogeneity existed (I2>50% or P<0.05), a random effect model was used to cal-
culate OR and RR. Otherwise a fixed effect model was used [26]. In order to explore the possi-
ble sources of heterogeneity, subgroup analyses and sensitivity analyses were conducted. In
addition, Egger’s test was used to evaluate the publication bias [27].
ALDH1 CSC in head and neck cancer
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Results
Description of the included studies
155 studies were retrieved from the databases and 14 studies [5, 16, 17, 28–38] met all prede-
fined inclusion criteria and therefore were included in the meta-analysis (Fig 1). The represen-
tative search strategies are illustrated in S1 File. The total number of patients included was
1258. The main characteristics of the eligible studies are summarized in Table 1. Ten articles
provided clinicopathological features, seven studies included data on OS and four studies
included data on DFS. The median follow-up of 7 studies is illustrated in Table 1. The patient
population of most studies was rather heterogeneous with patients of all clinical stages. Twelve
studies did not include patients with distant metastases. The percentage of patients with distant
metastases in the residual studies was 50% to 87.9% [16, 30]. HPV status was detected in four
studies. Subsites of primary tumors of twelve studies are illustrated in S1 Table including 413
oral cancers, 509 OPSCC and 177 at other sites. Information on treatment modalities was pro-
vided in only a single study. Therefore, treatment was not included in our statistical analysis.
Correlation of ALDH1 expression with clinicopathological parameters
All studies used immunohistochemistry (IHC) with cut-off values between any staining to
>10% positivity. Isoenzymes of ALDH1 are e.g., ALDH1A1, ALDH1A2, and ALDH1A3. The
antibodies used, when described, were specific for all isoforms of ALDH1 in four studies, and
ALDH1A1 in ten studies. Therefore, we used the term “ALDH1” in our analysis. The associa-
tion of ALDH1 expression with clinicopathological parameters is illustrated in Fig 2. ALDH1
expression was associated with higher differentiation grade (G3 vs. G1+G2; OR = 2.85, 95%
CI: 1.72–4.73, P<0.0001, fixed effect; Fig 2A) but not clinical stage (III+IV vs. I+II; OR = 1.34,
95% CI: 0.71–2.55, P = 0.37, fixed effect; Fig 2B). Sensitivity analysis showed stable results for
differentiation (S1 Fig). Furthermore, expression of ALDH1 was not significantly associated
Fig 1. Flow-chart for identification of eligible studies.
https://doi.org/10.1371/journal.pone.0187615.g001
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with positive lymph node status (Pos vs. Neg; OR = 1.93, 95% CI: 0.98–3.79, P = 0.06, random
effect; Fig 2C) or T-stage (T3+T4 vs. T1+T2; OR = 0.99, 95% CI: 0.71–1.38, P = 0.96, fixed
effect; Fig 2D). ALDH1 expression was analyzed in four studies regarding the tumor sites. The
studies of Koukourakis et al. and Ota et al. showed no significant relation of ALDHlow or
ALDHhigh expression to tumor sites.
ALDH1 expression and disease-free survival
DFS was investigated in 4 studies including 368 patients [17, 31–33]. We performed a meta-
analysis on the DFS of ALDH+ and ALDH- patients. There was no significant association
between ALDH1 expression and DFS (RR = 1.05; 95% CI: 0.35–3.16; P = 0.94, random effect;
Fig 3A), again with significant heterogeneity (P<0.0001; I2 = 88%). Then, we performed a sen-
sitivity analysis where omission of each single article’s data did not result in obvious change in
heterogeneity.
ALDH1 expression and 5-year overall survival outcome
We analyzed the OS of 672 patients from seven articles [5, 17, 29, 30, 33, 36, 37]. Using the
DerSimonian–Laird fixed effects model, the meta-analysis on the OS of ALDH+ and ALDH-
patients did not reach a statistical significance (RR = 1.44; 95% CI: 0.93–2.23, P = 0.10, random
effect; Fig 3B). The forest plot showed a high level of heterogeneity, which was significant (I-
Table 1. Main characteristics and results of the eligible studies.









Chen YW [29] 2010 Taiwan 111 HNSCC ND ND, Abcam ND ND 75 months
Koukourakis MI
[31]
2012 Greece 74 HNSCC I-III Rabbit mAb, EP1933Y,
Abcam
5% ND 24 months (4–80
months)
Michifuri Y [34] 2012 Japan 80 OSCC I-III Mouse mAb, clone 44, BD
Pharmingen
2% ND ND
Xu J [17] 2012 USA 96 HNSCC I-IV N-19, Santa Cruz 0 ND 62 months (12–
150 months)
Liu W [32] 2013 China 141 OSCC ND Rabbit mAb, ab52492,
Abcam
5% ND 66 months
Chen C [39] 2013 China 60 HNSCC ND ND, BD Biosciences ND ND ND
Qian X [16] 2013 Germany 80 OPSCC I-IV Mouse mAb, clone 44; BD
Biosciences
5% Yes ND
Ota N [35] 2014 Japan 90 OSCC I-IV Mouse mAb, clone 44; BD
Biosciences
5% ND ND
Zhang M [36] 2014 USA 222 OPSCC ND Mouse mAb, clone 44; BD
Biosciences
ND Yes ND
Huang CF [30] 2014 China 66 TSCC I-IV Polyclonal rabbit Ab,
Proteintech Group Inc.
10% ND 52 months (2–104
months)
Qian X [5] 2014 Germany 81 HNSCC I-III Mouse mAb, clone 44; BD
Biosciences
5% Yes ND
Leinung M [37] 2015 Germany 48 HNSCC ND Rabbit mAb, ab52492;
Abcam
ND Yes 120 months
Martı´n M [33] 2016 Spain 57 LSCC I-IV ND, Abcam ND ND 42 months
de Moraes FP
[38]
2016 Brazil 52 HNSCC I-IV EP1933Y, Abcam 10% ND ND
IHC: immunohistochemistry; HNSCC: head and neck squamous cell carcinoma; OSCC: oral squamous cell carcinomas; TSCC: tongue squamous cell
carcinoma; LSCC: laryngeal squamous cell carcinoma; OSCC: oral squamous cell cancer; OPSCC: oropharyngeal squamous cell carcinomas; ND: not
documented.
https://doi.org/10.1371/journal.pone.0187615.t001
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squared and Q-test, P = 0.0002; I2 = 77%). In order to show the individual influence of each
study on the over-all heterogeneity, we performed a sensitivity analysis by which each study
was removed from the pool of studies once and I2 and Q value was calculated. We demon-
strated that the study of Zhang et al. [36] was the source of heterogeneity (S2 Fig). The removal
of the latter study from the pooled population resulted in a significantly reduced I2 value. Anal-
ysis of the modified patient population showed a conspicuous shorter OS in patients with posi-
tive ALDH1 expression (RR = 1.77, 95% CI: 1.41–2.22, P<0.0001, random effect), which was
illustrated in the modified forest plot (Fig 3C).
Risk of bias of included studies and publication bias
Regarding to the NOS scale, all included studies had a score greater than 5 indicating a high
quality of each study (S2 Table). Begg’s funnel and Egger’s test were used to access the publica-
tion bias for each item (Table 2). Egger’s test showed no significant publication bias for T-
stage (t = 0.70, P = 0.508), lymph node status (t = 1.01, P = 0.352), differentiation grade
(t = 1.17, P = 0.306), OS (t = 0.83, P = 0.442) and DFS (t = -0.30, P = 0.792).
Discussion
ALDH1-expression is a commonly used marker identifying putative CSC in a variety of epi-
thelial tumors directly or indirectly, to identify cells displaying resistance to conventional
Fig 2. Forest plot describing the association between ALDH1 expression and odds ration (OR) for
clinical pathological features. Forest plot of OR for the (A) differentiation grading, (B) clinical staging, (C)
lymph node status, (D) tumor T stage of the ALDH1+ group compared to ALDH1- group.
https://doi.org/10.1371/journal.pone.0187615.g002
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cancer treatments [13]. In this meta-analysis, the presence of ALDH1-positive cells in HNSCC
was analyzed regarding tumor grading, stage at first diagnosis, and clinical outcomes. We
showed that the presence of ALDH1-positive cells within primary tumors was strongly associ-
ated with a higher grading, which means with more dedifferentiated tumors.
It is hypothesized that putative stem cells are not a defined subpopulation within the malig-
nant cells. The development from CSC to more differentiated cancer cells at the same tumor
site or after dissemination is believed to be continuous. Specific embryonic stem cell-associ-
ated transcriptional regulators and gene expression pathways appear to be more upregulated
in poorly differentiated but not in well differentiated tumors [40]. On a cellular level, some of
these transcriptional factors associated with embryonic stem cells, e. g., Sox2, Oct3/4, and
Fig 3. Meta-analysis for adjusted relative risk (RR) of the disease-free survival (DFS) or overall
survival (OS) compared to the ALDH1+ subgroup. Forest plot of RR among included studies for the DFS of
the ALDH1+ group compared to ALDH1- group (A). Forest plot of RR for the OS (B) and adjusted OS (C) of
the ALDH1+ group compared to ALDH1- group.
https://doi.org/10.1371/journal.pone.0187615.g003
Table 2. Egger’s test of funnel plot asymmetry.
Clinicopathological parameters t value df p value
Tumor grade 1.17 5 0.306
Lymph node metastasis 1.01 7 0.352
Tumor T stage 0.70 7 0.508
Overall survival 0.83 6 0.442
Disease free survival -0.30 3 0.792
df: degrees of freedom.
https://doi.org/10.1371/journal.pone.0187615.t002
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Nanog were significantly upregulated in ALDH1-postive CSC [41]. Accordingly, low-grade
tumors should contain mostly differentiated cells and few CSC, and high-grade tumors should
contain highly dedifferentiated cells exhibiting stem cell-like features and a high percentage of
CSC, a notion which we proved to be true in our meta-analysis. Recently, the dedifferentiation
from non-CSC into ZsGreen-cODC-positive CSC, a subpopulation of ALDH1-positive cells,
was found in both HPV-negative and HPV-positive HNSCC cell lines in response to radiation
[42]. Moreover, HPV-positive HNSCC cells that survived radiation dedifferentiated in CSC at
lower rates while HPV-negative HNSCC had a higher rate. This phenomenon not only dem-
onstrates that dedifferentiation exists during radiotherapy and thus the capacity of CSC for
repopulation, but also explains in part the better survival for patients with HPV-positive
HNSCC. However, very little is known of whether a dedifferentiation from non-CSC to CSC
on a cellular level is possible. What is known is that epithelial-mesenchymal transition (EMT)
and its reversed process mesenchymal-epithelial transition is related to the acquisition of stem
cell properties. It appears that EMT can reprogram differentiated mammary epithelial cells
into less differentiated epithelial stem cells with mesenchymal traits [43]. It also has been dem-
onstrated in HNSCC that overexpression of ALDH1 dramatically decreased expression of epi-
thelial markers but increased expression of mesenchymal markers [4] leading to enhanced
invasiveness and metastatic potential [44]. A better understanding of how and why CSC are
induced and modulated local-regionally might suggest ways to target them.
HNSCC is used to describe all carcinomas arising from the stratified squamous epithelium
lining the sinonasal tract, oral cavity, oropharynx, pharynx, and larynx. Histologically, squa-
mous cell carcinoma is characterized by microscopic evidence of squamous differentiation
and invasive growth. In most cases, the histological grading of these tumors is directly linked
to the clinical stage at first diagnosis. At least for oral HNSCC, poorly differentiated tumors are
more likely correlated with a positive nodal status, extracapsular spread, and perineural inva-
sion [45]. Given the fact, that we found a clear association of ALDH1-expression with high his-
tological grade, we expected an association of ALDH1 expression with clinical stage, T- and N-
status. In a previous meta-analysis, Zhou et al. showed that the ALDH1 expression was signifi-
cantly associated with lymph node metastasis, but not T-stage and the presence of distant
metastases [46]. However, our analysis did not show significant impact of ALDH1 expression
on disease stage. The discrepancy of the results may be due to the recent publications [33, 35,
36] enrolled in the dataset which have shown no significant correlations between lymph node
metastasis and CSC. Although a significant correlation of ALDH1 CSC with nodal status was
not concluded in this meta-analysis, in patterns of primary tumor and its corresponding nodal
metastases, we (Qian et al.) showed that the proportion of ALDH1-expressing cells was signifi-
cantly increased in nodal metastases compared to their corresponding primary tumors [16].
We also observed in vitro as a property of CSC an increased invasive capacity and expression
of EMT-markers and decreased expression of adhesion molecule E-cadherin [4]. In addition,
the EMT process can be reversed by transfer of miR34a-mimics into HNSCC cells [41]. We
are currently planning a morphoproteomics-based prospective study to further investigate the
outcome of HNSCC regarding CSC and EMT markers in order to tailor the possibility of bio-
marker-directed therapy.
In addition, HPV status may also be responsible for discrepant results. There was no corre-
lation between ALDH1 expression and nodal metastases when only HPV- tumors were
included in the study of Leinung et al. [37]. The study by Zhang et al. [36] showed that
HPV16+ OPSCC had a higher intrinsic CSC pool than HPV- OPSCC and no correlation was
found between nodal status and ALDH1 positive CSC for the whole cohort. Because the
authors did not perform the subgroup analysis based on HPV status, the frequency of CSC in
HPV+ and HPV- tumors was not documented. According to the recent report of global
ALDH1 CSC in head and neck cancer
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incidence of HPV infection in head and neck cancer [47], around 30% of OPSCC are caused
by HPV, followed by oral cavity and larynx. The majority of subsites included in this meta-
analysis are OPSCC, oral cavity and larynx. Thus, discrimination on HPV status to assess the
effect of ALDH1 expression on lymph node metastasis is helpful to confirm or rebut this
hypothesis.
The weakness of our meta-analysis is mainly the heterogeneity of studies and lack of clinical
data. We could not find a statistical difference in DFS, which is a discrepancy compared to a
previously published evaluation [46]. Indeed, several factors may account for the discrepancy of
survival between two datasets. While the study by Liu et al. showed a clear signal for ALDH1
being associated with a shorter PFS, Martin et al. found the opposite result. Here it is important
to note that the study by Liu et al. only included carcinomas of oral cavity [32]. Martin et al., on
the other hand, included only laryngeal carcinomas with a portion of 26% stage IV patients
[33]. Anatomic site, stage and histological characteristics are considered to be of importance for
risk stratification of HNSCC [48–50]. As shown in a recent report by The Cancer Genome Atlas
Network [51], increased expression of oxidative stress response genes associated with chemo-
resistance was found in laryngeal carcinomas while oral cavity tumors exhibit lower expression
of genes related to DNA repair. Other confounding factors may include different ALDH1 test-
ing methods used in each study and different treatment protocols. The prognostic impact of
ALDH1 positivity on OS in HNSCC patients has been detected in seven of fourteen studies.
When one source study was excluded, there was a significant impact of ALDH1 positivity on
OS. Again, the observed heterogeneity of the patient populations is more likely to be responsible
for the equivocal findings. The study by Zhang et al. [36] included exclusively HPV+ LA tumors
which was associated with a favorable outcome than HPV- LA tumors [52]. Also, differences do
exist in the CSC pool of HPV+ tumors and HPV- tumors [16, 42]. There are disagreements
between the study of Zhang et al. where HPV+ HNSCC cells had a greater intrinsic CSC pool
and other studies which showed a significantly lower frequency of CSCs in HPV+ tumors [42,
53]. In addition, because the patient samples enrolled in the Zhang study were microarrays,
there would be limitations to conclude the results based on the selected tumor cores. They
observed ALDH1 staining in>50% of the tumor cells in selected HPV- and HPV16+ OPSCC
tumor cores. However, in our own study, the ALDH1 staining ranged from 0 to>50% in pri-
mary tumor and its corresponding nodal metastases. We also found higher ALDH1 expression
grades and negative HPV status for primary tumors but not for metastases. These findings are
consistent with studies in HNSCC cell lines which have shown HPV+ cell lines had lower num-
bers of CSCs [41] and inversely correlated with radiosensitivity [42]. Although these studies
seem contradictory, it is worth noting that a small proportion of less radioresistant CSCs being
identified in HPV-induced HNSCC were positively associated with decreased local regional
control [54] indicating a contribution of CSC to the decreased local regional control in HPV+
tumors. The reason behind the observed differences warrants further investigations.
It is clear that CSC play crucial roles in tumorigenesis based on earlier observations, but
currently its clinical relevance such as its proportions in pre- and post-treatment stage,
response to treatment modalities and outcomes is still limited. The data revealed that ALDH1
expression is associated with tumor histology independent of HPV status indicating ALDH1-
positive CSC as a potentially valuable tool in clinical management of HNSCC. The data also
revealed the potentially prognostic value of ALDH1-positive CSC in HNSCC. It is necessary to
further investigate the value of CSC presence as markers in stratified HNSCC subgroups based
on factors such as HPV-association or tumor site. Treatment modalities targeting CSC popula-
tions in order to improve therapy are also currently of interest. Kulsum et al. demonstrated
that ALDH1A1 inhibition improved the effectiveness of cisplatin treatment, reduced the
migration rate, self-renewal capacity and tumorigenicity of cancer cells in vitro. Further, an ex
ALDH1 CSC in head and neck cancer
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vivo study continuously showed that ALDH1A1-specific inhibitor in combination with cis-
platin significantly decreased the proliferation of cells as compared to individual treatment
[18]. Thus, strategies to introduce ALDH1A1-specific inhibitors to current chemoradiother-
apy regimens, in an effort to target CSC and treatment-induced reprogramming, may become
an ideal treatment to achieve better curative effects.
In conclusion, we have presented that ALDH1 expression is associated with tumor histol-
ogy and has potential prognostic value independent of etiologies such as chronic alcohol,
tobacco abuse, and HPV status in the meta-analysis. Additional limitations of our meta-analy-
sis are the number of included articles and that the sample size of each study was rather small.
There was heterogeneity of data among outcomes. We acknowledge that because of the limited
data for our question of interest such as HPV status and tumor subsites were not discrimi-
nated, the strength of our conclusion is limited. Given the massive biases built in to case-con-
trol studies, ALDH1 as a putative biomarker should (at most) be presented as speculative.
Future large-scale prospective studies to establish and validate the prognostic value of ALDH1
are necessary.
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